| BMS-303141ATP-citrate lyase inhibitor,potent |

Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.
Nature.2018 Jun 13.
Nature.2018 Jun 27.
Nature.2018 Mar 29;555(7698):673-677.
Nature.2017 Sep 7;549(7670):96-100.
Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8
Nat Nanotechnol.2017 Dec;12(12):1190-1198.
Nature Biotechnology.2017 Jun;35(6):569-576
Nat Med.2018 Sep 17.
Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.
Cell.Available online 25 October 2018.
Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.
Cell.2018 Jun 28;174(1):172-186.e21.
Cell.2018 Feb 22;172(5):1007-1021.e17.
Cell.2017 Nov 30;171(6):1284-1300.e21.
Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.
Cell.2017 Jul 13;170(2):312-323
Nat Med.2018 Jan 29.
Nat Med.2017 Nov;23(11):1342-1351.
Cell.2017 Apr 6;169(2):286-300.
Cell.2015 Aug 27;162(5):987-1002.
Cell.2015 Feb 12;160(4):729-44.
Nature Medicine.2017 Apr;23(4):493-500.
Cancer Cell.2018 May 14;33(5):905-921.e5.
Cancer Cell.2018 Apr 9;33(4):752-769.e8.
Cancer Cell.2018 Mar 12;33(3):401-416.e8.
Cancer Cell.2017 Aug 14;32(2):253-267.e5.
Nat Methods.2018 Jul;15(7):523-526.
Cell Stem Cell.2018 May 3;22(5):769-778.e4.
Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.51%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure

| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation method | The solubility of this compound in DMSO is > 21.2 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition | 8 μM; 6 hrs |
Applications | In HepG2 cells, BMS-303141 inhibited total lipid synthesis with an IC50 value of 8 μM. Moreover, BMS-303141 showed no cytotoxicity up to 50 μM. |
| Animal experiment [1]: | |
Animal models | High-fat fed mice |
Dosage form | 10 and 100 mg/kg; p.o. |
Applications | In high-fat fed mice, BMS-303141 modestly reduced both plasma cholesterol and triglyceride 20 days after treatment. In addition, fasting plasma glucose started to decrease from day 7 to completion of the study. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Li JJ, Wang H, Tino JA, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett, 2007, 17(11): 3208-3211. | |

BMS-303141 Dilution Calculator
calculate

BMS-303141 Molarity Calculator
calculate
| Cas No. | 943962-47-8 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | 3,5-dichloro-2-hydroxy-N-(4-methoxy-[1,1"-biphenyl]-3-yl)benzenesulfonamide | ||
| Canonical SMILES | COC1=C(NS(C2=CC(Cl)=CC(Cl)=C2O)(=O)=O)C=C(C3=CC=CC=C3)C=C1 | ||
| Formula | C19H15Cl2NO4S | M.Wt | 424.3 |
| Solubility | ≥21.2mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 μM [1].
ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids. Inhibition of ACL is used to treat dyslipidemia and obesity [1].
BMS-303141 is a potent ATP-citrate lyase inhibitor. In HepG2 cells, BMS-303141 inhibited total lipid syntheses with IC50 value of 8 μM. Also, BMS-303141 showed no cytotoxicity up to 50 μM [1].
In mice, BMS-303141 exhibited an oral bioavailability of 55%. In high-fat fed mice, BMS-303141 reduced the levels of plasma triglyceride, cholesterol by 20-30% and glucose by 30-50% and inhibited weight gain [1]. BMS-303141 inhibited ACL with IC50 value of 0.94 μM for human ACL in a concentration dependant way [2].
References:[1]. Li JJ, Wang H, Tino JA, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett, 2007, 17(11): 3208-3211.[2]. Ma Z, Chu CH, Cheng D. A novel direct homogeneous assay for ATP citrate lyase. J Lipid Res, 2009, 50(10): 2131-2135.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
启动子是RNA聚合酶能够识别并与之结合,从而起始基因转录的一段DNA序列,通常位于基因上游.一个典型的启 动子包括CAAT-box和TATA-box,它们分别依赖DNA的RNA聚合酶的识别和结合位点,一般位于转录起始位点上游几十个碱基处.在核心启动子上 游通常会有一些特殊的DNA序列,即顺式作用元件,转录因子与之结合从而激活或抑制基因的转录.一旦RNA聚合酶定位并结合在启动子上即可 启动基因转录,因此启动子是基因表达调控的重要元件,它与RNA聚合酶及其他蛋白辅助因子等反式作用因子的相互作用是启动子调控基因转录的实质.
根据启动子的转录模式可将其分为3类:组成型启动子、组织或器官特异性启动子和诱导型启动子.
似乎都是鉴定目的基因是否导入受体细胞 没有鉴定是否成功导入质粒的 鉴定目的基因是否导入受体细胞有四个层次 1 直接鉴定受体细胞中是否有目的基因 用DNA分子杂交 2 鉴定目的基因是否转录 分子杂交(mRNA) 3 目的基因是否表达 抗原-抗体 (蛋白质) 4 看受体细胞发育成的个体是否表现出相关性状
各位大神,我现在用PET28α作为表达载体,在连接的时候是不是载体要进行双酶切、胶回收?我双酶切的目的片段和PET28α连接后,导入感受态中没有成功,不知道怎么回事,请教各位。
2、基因表达载体的构建
(1)目的:使目的基因在受体细胞中稳定存在并且可以遗传给下一代并表达和发挥作用.(2)基因表达载体的组成:目的基因+启动子+终止子+标记基因
②启动子在基因的首段,它是RNA聚合酶的结合位点,能控制着转录的开始,故②正确;
③终止子在基因的尾端,它控制着转录的结束,故③正确;
④由于受体细胞有植物、动物以及微生物之分,以及目的基因导入受体细胞的方法不同,因此基因表达载体的构建是不完全相同的,

